BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31279293)

  • 1. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.
    Gregson SJ; Barrett AM; Patel NV; Kang GD; Schiavone D; Sult E; Barry CS; Vijayakrishnan B; Adams LR; Masterson LA; D'Hooge F; Snaith M; Harper J; Hartley JA; Howard PW
    Eur J Med Chem; 2019 Oct; 179():591-607. PubMed ID: 31279293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
    Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
    ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
    Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
    Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
    Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
    J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.
    Pei Z; Chen C; Chen J; Cruz-Chuh JD; Delarosa R; Deng Y; Fourie-O'Donohue A; Figueroa I; Guo J; Jin W; Khojasteh SC; Kozak KR; Latifi B; Lee J; Li G; Lin E; Liu L; Lu J; Martin S; Ng C; Nguyen T; Ohri R; Lewis Phillips G; Pillow TH; Rowntree RK; Stagg NJ; Stokoe D; Ulufatu S; Verma VA; Wai J; Wang J; Xu K; Xu Z; Yao H; Yu SF; Zhang D; Dragovich PS
    Mol Pharm; 2018 Sep; 15(9):3979-3996. PubMed ID: 30040421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
    Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
    Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
    Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).
    Mantaj J; Jackson PJ; Rahman KM; Thurston DE
    Angew Chem Int Ed Engl; 2017 Jan; 56(2):462-488. PubMed ID: 27862776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
    Staben LR; Chen J; Cruz-Chuh JD; Del Rosario G; Go MA; Guo J; Khojasteh SC; Kozak KR; Li G; Ng C; Lewis Phillips GD; Pillow TH; Rowntree RK; Wai J; Wei B; Xu K; Xu Z; Yu SF; Zhang D; Dragovich PS
    J Med Chem; 2020 Sep; 63(17):9603-9622. PubMed ID: 32787101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.
    Dragovich PS; Broccatelli F; Chen J; Fan P; Le H; Mao W; Pillow TH; Polson AG; Wai J; Xu Z; Yao H; Zhang D
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5300-5304. PubMed ID: 29079474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads.
    Donnell AF; Zhang Y; Stang EM; Wei DD; Tebben AJ; Perez HL; Schroeder GM; Pan C; Rao C; Borzilleri RM; Vite GD; Gangwar S
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5267-5271. PubMed ID: 29102228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate.
    Vlahov IR; Qi L; Santhapuram HKR; Felten A; Parham GL; Zou N; Wang K; You F; Vaughn JF; Hahn SJ; Klein HF; Kleindl PJ; Reddy J; Reno D; Nicoson J; Leamon CP
    Bioorg Med Chem Lett; 2020 Apr; 30(7):126987. PubMed ID: 32029324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
    Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
    Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs).
    Janaratne T; Wang XC; Becker C; Zhao Y; Leanna R; Pritts W
    J Pharm Biomed Anal; 2020 Feb; 179():113027. PubMed ID: 31830625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of PBD Dimers by Lipophilicity Manipulation.
    Cailleau T; Adams LR; Arora N; Kang GD; Masterson L; Patel N; Hartley JA; Mao S; Harper J; Howard PW
    Curr Top Med Chem; 2019; 19(9):741-752. PubMed ID: 30931859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
    Corbett S; Huang S; Zammarchi F; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2020 Sep; 19(9):1856-1865. PubMed ID: 32669316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.